Overview

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma

Status:
Completed

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

This multicentre, open-label, randomized phase II trial is ongoing in 30 centres in France. Main eligibility criteria include: histologically proven adenocarcinoma of the stomach, esophagus or gastroesophageal junction; locally advanced or metastatic disease; measurable disease (RECIST 1.1); no known HER2 overexpression; no prior palliative chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

UNICANCER

Treatments:

Antibodies, Monoclonal
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin
Panitumumab
Rilotumumab